2026-06-17T13:51:56+00:00 2025-12-31 135381590 BDO USA 421 FAYETTEVILLE ST STE 300 RALEIGH NC 276011776 990 2025-01-01 526063009 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FDN INC PHAR 2025727756 670 MAINE AVENUE SW 1000 WASHINGTON DC 20024 AMY MILLER PRESIDENT 2025727755 2026-06-17 true SANDRA L FEINSMITH P01064157 9197549370 2026-06-17 2025 2025-03-06 01:10:19Z AMY MILLER 670 MAINE AVENUE SW 1000 WASHINGTON DC 20024 11443308 false X WWW.PHRMAFOUNDATION.ORG X 1965 DC THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE DRIVEN HEALTH CARE. 9 9 4 85 0 3705380 2829510 0 0 587753 2073089 0 0 4293133 4902599 3479307 3708833 0 0 1136663 1144793 0 0 3234 365891 347603 4981861 5201229 -688728 -298630 27568119 28801189 1540685 1517326 26027434 27283863 X THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE. false false 1341859 1085952 0 Drug Discovery - funds early career academic scientists who are pioneering new approaches to drug discovery. We support research projects that have the potential to make a significant impact for patients. By funding the drug discovery research of promising young scientists, the Foundation helps accelerate the identification of new therapeutic compounds and modalities while building a talent base to support innovation across the biopharmaceutical industry. 1055367 856250 0 Drug Delivery - Funds researchers studying ways to optimize drug composition, dosage, and delivery to make treatments safer, more effective, and easier to manage for patients. 901315 739986 0 Value Assessment-Health Outcomes Research (VA-HOR) - supports early career researchers engaged in a multidisciplinary, collaborative research that investigates challenges and potential solutions related to evaluating the delivery, safe use, effectiveness, and value (clinical, patient-centered, and economic) of medicines and other health care interventions. 864045 693309 0 Translational Medicine - Funds novel research that uses the "bedside to bench" approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation supports early career researchers focused on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management. 410148 333336 0 DIGITAL HEALTH TECHNOLOGIES - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. 61365 0 0 Other Program Expenses 1335558 1026645 4634099 true true false false false false false false false false true false false false true true true false false false false false true false false false false false true true false false false false false false false false false false false false false false false false false false false false true 56 0 true 4 true false false false false false false false false false false false false X 9 9 false false false false false true false true true false false false true true true true true true true true false false CA CT IL MD MA NJ NY NC PA X KIMBERLY SIDHU 2028353400 670 MAINE AVENUE SW SUITE 1000 WASHINGTON DC 20024 X ANDREW PLUMP MD PHD CHAIRMAN 1.0 0 X X 0 0 0 AIDA HABTEZION MD MSC FRCP DIRECTOR (THRU 3/2025) 1.0 0 X 0 0 0 DANIEL SKOVRONSKY MD PhD DIRECTOR 1.0 0 X 0 0 0 DONATELLO CROCETTA Director 1.0 0 X 0 0 0 FIONA H MARSHALL PHD FMedSci FRS DIRECTOR (AS OF 6/2025) 1.0 0 X 0 0 0 GEORGE ADDONA PHD DIRECTOR 1.0 0 X 0 0 0 JOHN REED MD PhD DIRECTOR 1.0 0 X 0 0 0 LORI REILLY Esq EX OFFICIO MEMBER 1.0 0 X 0 0 0 PATRIZIA CAVAZZONI MD DIRECTOR (AS OF 6/2025) 1.0 0 X 0 0 0 ROBERT PLENGE MD PHD DIRECTOR 1.0 0 X 0 0 0 AMY MILLER PRESIDENT 37.5 0 X 535515 0 78411 EMILY ORTMAN SENIOR DIRECTOR 37.5 0 X 204960 0 64962 JOANNE WESTPHAL DIRECTOR 37.5 0 X 184732 0 37717 925207 0 181090 3 false true false O'CONNOR CONSULTING SERVICES LLC 6507 MARJORY LANE BETHESDA MD 20817 ACCT, FINANCIAL STATEMENT & TAX PREPARATION 0 0 0 0 0 0 2829510 0 2829510 0 0 0 0 0 555640 0 0 555640 0 0 8058158 0 6540709 0 1517449 0 1517449 0 0 1517449 0 0 0 0 0 0 4902599 0 0 2073089 0 0 3698833 3698833 10000 10000 0 0 613926 442827 171099 0 0 0 0 0 326105 235221 90884 0 70483 50840 19643 0 74207 53526 20681 0 60072 43330 16742 0 0 0 0 0 0 0 0 0 31130 0 31130 0 0 0 0 0 0 0 51244 0 51244 0 150570 34000 116570 0 9492 352 9140 0 1800 1461 339 0 13980 13681 299 0 0 0 0 0 0 0 0 0 16608 6959 9649 0 0 0 0 0 15575 11719 3856 0 0 0 0 0 0 0 0 0 32727 23606 9121 0 9651 6961 2690 0 Bank/Payroll Charges 9771 0 9771 0 Dues/Publications/Projects 5055 783 1038 3234 0 0 0 0 5201229 4634099 563896 3234 2768034 2405817 0 0 0 0 0 0 0 0 0 0 0 0 0 0 18563 19527 98178 70906 59998 27272 24721524 26348573 0 0 0 0 0 0 27568119 28801189 1517703 1505330 0 0 0 0 0 0 0 0 0 0 0 0 0 0 22982 11996 1540685 1517326 X 26027434 27283863 0 0 26027434 27283863 27568119 28801189 X -298630 1480206 0 0 0 74853 X X false true true false X 2764822 3535607 3576216 3705380 2829510 16411535 0 0 0 0 0 0 0 0 0 0 0 0 2764822 3535607 3576216 3705380 2829510 16411535 10554777 5856758 407496 460897 496762 600608 555640 2521403 0 0 0 0 0 0 0 0 0 0 0 0 18932938 0 0.30934 0.30853 X Schedule A, Part II PART II, SECTION C, LINE 17A, FACTS AND CIRCUMSTANCES TEST: In 2025, the Foundation continued its efforts to increase and diversify its base of public support through expanded educational programming, public outreach, and donor engagement activities. Management conducted outreach throughout the year with prospective donors, including individuals, corporations, and philanthropic organizations. The Foundation also solicits contributions through its publicly accessible website with a dedicated donations page. The Foundation operates exclusively for charitable and educational purposes and provides broad public benefit through its national grants, awards, and educational content. Its funding opportunities are available to eligible applicants throughout the United States. The Foundation develops and freely distributes educational content to the general public through its website, newsletters, and social media platforms, including YouTube, LinkedIn, and X (formerly Twitter). This content includes webinars, videos, blogs, and career-development resources related to biomedical research, drug discovery, health outcomes research, scientific training and grant funding opportunities. The Foundation's governing board is composed of leaders who are dedicated to strengthening the scientific workforce. They have significant experience in research and development and the fields of pharmaceutical research and healthcare delivery. The board oversees scientific programs that foster research and enhance public knowledge. The board regularly evaluates and updates fundraising and outreach strategies to expand awareness of the Foundation's mission and broaden public support from a diverse range of contributors. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 98178 70906 27272 27272 Federal Income Taxes INTERCOMPANY SETTLEMENT 11996 11996 X 6387805 1480206 56244 0 1536450 4851355 51244 0 51244 4902599 5131376 56244 -74853 -18609 5149985 51244 0 51244 5201229 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND CONCLUDED THAT THE FOUNDATION HAS NOT TAKEN ANY UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS. AT A MINIMUM, THE TAX PERIODS ENDED DECEMBER 31, 2022 AND LATER ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 Refunded Grants - -74853 Value Assmt - Health Outcomes Rsrch East Asia and the Pacific 1 5000 wire Drug Delivery North America (Canada & Mexico only) 1 5000 wire false false false false false false Schedule F, Part III Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC -Accrual NORTH AMERICA (CANADA & MEXICO ONLY) -Accrual true DRUG DISCOVERY 41 1085952 DRUG DELIVERY 23 851250 VALUE ASSMT-HEALTH OUTCOMES RSRCH 19 734986 TRANSLATIONAL MEDICINE 18 693309 DIGITAL HEALTH TECHNOLOGY 2 333336 Schedule I, Part III DRUG DISCOVERY - FUNDS EARLY CAREER ACADEMIC SCIENTISTS WHO ARE PIONEERING NEW APPROACHES TO DRUG DISCOVERY. WE SUPPORT RESEARCH PROJECTS THAT HAVE THE POTENTIAL TO MAKE A SIGNIFICANT IMPACT FOR PATIENTS. BY FUNDING THE DRUG DISCOVERY RESEARCH OF PROMISING YOUNG SCIENTISTS, THE FOUNDATION HELPS ACCELERATE THE IDENTIFICATION OF NEW THERAPEUTIC COMPOUNDS AND MODALITIES WHILE BUILDING A TALENT BASE TO SUPPORT INNOVATION ACROSS THE BIOPHARMACEUTICAL INDUSTRY. DRUG DELIVERY - FUNDS RESEARCHERS STUDYING WAYS TO OPTIMIZE DRUG COMPOSITION, DOSAGE, AND DELIVERY TO MAKE TREATMENTS SAFER, MORE EFFECTIVE, AND EASIER TO MANAGE FOR PATIENTS. VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH (VA-HOR) - SUPPORTS EARLY CAREER RESEARCHERS ENGAGED IN A MULTIDISCIPLINARY, COLLABORATIVE RESEARCH THAT INVESTIGATES CHALLENGES AND POTENTIAL SOLUTIONS RELATED TO EVALUATING THE DELIVERY, SAFE USE, EFFECTIVENESS, AND VALUE (CLINICAL, PATIENT-CENTERED, AND ECONOMIC) OF MEDICINES AND OTHER HEALTH CARE INTERVENTIONS. TRANSLATIONAL MEDICINE - FUNDS NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF DISEASE. THE FOUNDATION SUPPORTS EARLY CAREER RESEARCHERS FOCUSED ON IDENTIFYING UNMET CLINICAL NEEDS AND DEVELOPING NEW DIAGNOSTIC, EXPERIMENTAL, AND COMPUTATIONAL APPROACHES AND TECHNOLOGIES TO IMPROVE PATIENT CARE AND MANAGEMENT. DIGITAL HEALTH TECHNOLOGIES - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds Grants and fellowships are made to individual pre- and post-doctorate candidates based on their individual application. Once awarded, funds are remitted to the recipient's hosting, US-based institution specifically earmarked for the awardee. The second and third years of funding, if applicable, are contingent upon a satisfactory review of the award recipient's progress during the first 10 months of funding. A progress report is due to the Foundation prior to the beginning of the second year of funding. The report is assessed by the advisory committee, and if it adheres to the funded research project on which the award was based, funding continues. In addition to the progress report, the Foundation must receive certification from the institution that satisfactory progress is being achieved for predoctoral and postdoctoral fellowships and that the awardee is still affiliated with the institution. A financial report is due to the Foundation from the institution after the first year of funding and following the end of the funding period for all awards. The institution must stipulate the amount of funds received and how the funds have been used or spent. Unspent funds must be returned to the Foundation at the end of the award cycle. X true true X X false false false false false false false false false AMY MILLER PRESIDENT 369848 0 163700 0 1967 0 35000 0 43411 0 613926 0 0 0 EMILY ORTMAN SENIOR DIRECTOR 167806 0 34136 0 3018 0 19490 0 45472 0 269922 0 0 0 JOANNE WESTPHAL DIRECTOR 159922 0 20675 0 4135 0 18640 0 19077 0 222449 0 0 0 Schedule J, Part I, Line 1a Health or social club dues or initiation fees Health and wellness benefit: All PhRMA Foundation Employees are eligible to participate in the organization's health and wellness benefit up to $1,250 annually. The value of this benefit is considered taxable income. Form 990, Part III, Line 4d Description of other program services (Expenses $ 864,045 including grants of $ 693,309)(Revenue $ 0) Translational Medicine - Funds novel research that uses the "bedside to bench" approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation supports early career researchers focused on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management. Form 990, Part III, Line 4d Description of other program services (Expenses $ 410,148 including grants of $ 333,336)(Revenue $ 0) DIGITAL HEALTH TECHNOLOGIES - SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. Form 990, Part III, Line 4d Description of other program services (Expenses $ 61,365 including grants of $ 0)(Revenue $ 0) Other Program Expenses Form 990, Part VI, Line 15 PROCESS TO ESTABLISH COMPENSATION OF TOP MANAGEMENT OFFICIAL Merit raises and bonuses are determined in accordance with PhRMA policy based on staff evaluations, and recommendations are forwarded to the President for review. Overall performance of the President of the Foundation, including merit raises and bonuses, is also determined in accordance with PhRMA policy based on staff evaluations by the Ex-Officio member of the Foundation Board. This evaluation and recommendations are forwarded to the Board Chair for final approval of the President's performance, including compensation/bonus. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body THE CHIEF OPERATING OFFICER OF THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), A SECTION 501(C)(6) TRADE ASSOCIATION THAT HAS A HISTORIC AND CONTINUING RELATIONSHIP WITH THE FOUNDATION, IS AN EX-OFFICIO MEMBER OF THE FOUNDATION'S BOARD OF DIRECTORS. FOUNDATION DIRECTORS MUST BE RESEARCH AND DEVELOPMENT EXECUTIVES OR CHIEF MEDICAL OFFICERS OF COMPANIES THAT ARE MEMBERS OF PHRMA, BUT ARE ELECTED BY THE FOUNDATION BOARD ITSELF. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FOUNDATION'S FORM 990 IS PREPARED BY BDO USA, CPAS, AND REVIEWED INTERNALLY BY KEY FINANCIAL MANAGEMENT AND THE FOUNDATION'S PRESIDENT. A COPY OF THE 990 IS PROVIDED TO THE BOARD OF DIRECTORS TO REVIEW PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES OF THE FOUNDATION MUST REPORT POTENTIAL AND ACTUAL CONFLICTS AS THEY ARISE. IN ADDITION, THEY ARE REQUIRED TO SIGN AN ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT. WHEN A POTENTIAL CONFLICT OF INTEREST IS DISCLOSED TO, OR OTHERWISE COMES TO THE ATTENTION OF, THE PRESIDENT, THE CHAIR OF THE BOARD OR A NON-AFFECTED DIRECTOR, HE OR SHE SHALL CONSIDER ALL THE RELEVANT CIRCUMSTANCES AND SHALL DETERMINE WHETHER THE ARRANGEMENT IS POTENTIALLY HARMFUL TO THE BEST INTERESTS OF THE FOUNDATION. IF THE ARRANGEMENT IS FOUND NOT TO BE HARMFUL, THEN THE ARRANGEMENT MAY BE AUTHORIZED OR APPROVED; OTHERWISE, THE DIRECTOR, OFFICER OR KEY EMPLOYEE WHO IS INVOLVED OR EXPECTS TO BE INVOLVED IN THE ARRANGEMENT SHALL BE NOTIFIED THAT THE ARRANGEMENT IS NOT AUTHORIZED OR APPROVED AND, IF ALREADY IN EXISTENCE, SHOULD BE TERMINATED. THE PRESIDENT SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY AFTER CONSULTING WITH THE CHAIR OF THE BOARD. THE CHAIR OF THE BOARD SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY UPON A VOTE OF A MAJORITY OF UNINVOLVED DIRECTORS. Form 990, Part VI, Line 19 Required documents available to the public THE FOUNDATION DOES NOT MAKE ITS GOVERNING DOCUMENTS OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. Form 990, Part XI, Line 9 Other changes in net assets or fund balances GRANT REFUNDS - 74853; Total - 74853; Form 990, Part XII, Line 2c Change of oversight process or selection process THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.